Allocation to highly sensitized patients based on acceptable mismatches results in low rejection rates comparable to nonsensitized patients

Whereas regular allocation avoids unacceptable mismatches on the donor organ, allocation to highly sensitized patients within the Eurotransplant Acceptable Mismatch (AM) program is based on the patient\'s HLA phenotype plus acceptable antigens. These are HLA antigens to which the patient never made antibodies, as determined by extensive laboratory testing. AM patients have superior long-term graft survival compared with highly sensitized patients in regular allocation. Here, we questioned whether the AM program also results in lower rejection rates. From the PROCARE cohort, consisting of all Dutch kidney transplants in 1995-2005, we selected deceased donor single transplants with a minimum of 1 HLA mismatch and determined the cumulative 6-month rejection incidence for patients in AM or regular allocation. Additionally, we determined the effect of minimal matching criteria of 1 HLA-B plus 1 HLA-DR, or 2 HLA-DR antigens on rejection incidence. AM patients showed significantly lower rejection rates than highly immunized patients in regular allocation, comparable to nonsensitized patients, independent of other risk factors for rejection. In contrast to highly sensitized patients in regular allocation, minimal matching criteria did not affect rejection rates in AM patients. Allocation based on acceptable antigens leads to relatively low-risk transplants for highly sensitized patients with rejection rates similar to those of nonimmunized individuals

Allocation to highly sensitized patients based on acceptable mismatches results in low rejection rates comparable to nonsensitized patients

Whereas regular allocation avoids unacceptable mismatches on the donor organ, allocation to highly sensitized patients within the Eurotransplant Acceptable Mismatch (AM) program is based on the patient's HLA phenotype plus acceptable antigens. These are HLA antigens to which the patient never made antibodies, as determined by extensive laboratory testing. AM patients have superior long-term graft survival compared with highly sensitized patients in regular allocation. Here, we questioned whether the AM program also results in lower rejection rates. From the PROCARE cohort, consisting of all Dutch kidney transplants in 1995-2005, we selected deceased donor single transplants with a minimum of 1 HLA mismatch and determined the cumulative 6-month rejection incidence for patients in AM or regular allocation. Additionally, we determined the effect of minimal matching criteria of 1 HLA-B plus 1 HLA-DR, or 2 HLA-DR antigens on rejection incidence. AM patients showed significantly lower rejection rates than highly immunized patients in regular allocation, comparable to nonsensitized patients, independent of other risk factors for rejection. In contrast to highly sensitized patients in regular allocation, minimal matching criteria did not affect rejection rates in AM patients. Allocation based on acceptable antigens leads to relatively low-risk transplants for highly sensitized patients with rejection rates similar to those of nonimmunized individuals

Cationic ansa-(η5-Cyclopentadienyl)(η6-arene) Complexes of Titanium

The half-sandwich titanium trimethyl complex (η5-C5H4CMe2Ar)TiMe3 (Ar = 3,5-Me2C6H3) reacts with the Lewis acid B(C6F5)3 to give the ionic TiIV ansa-cyclopentadienyl-arene complex [(η5,η6-C5H4CMe2Ar)TiMe2][MeB(C6F5)3]. In bromobenzene solvent, addition of more B(C6F5)3 leads to C6F5/Me exchange and, subsequently, to formation of an unusual dimeric TiIII dicationic species, {[(η5,η6-C5H4CMe2Ar)Ti(μ-Br)]2}[B(C6F5)4]2, which was structurally characterized. Its formation involves reduction of the transition-metal center, solvent C–Br cleavage and perfluoroaryl-group scrambling.

Sensitivity of magnetoencephalography as a diagnostic tool for epilepsy:a prospective study

Aim. The diagnostic process for epilepsy can be lengthy and stressful, which may delay the start of treatment. The objective of this study was to determine the benefit of routine magnetoencephalography (MEG) with regard to diagnostic gain, compared to routine electroencephalography (EEG), EEG following sleep deprivation (EEGsd), and 24-hour EEG. Methods. In this prospective study, patients were included from two centres (Academic Centre for Epileptology Kempenhaeghe, Heeze and Elisabeth-Twee Steden Hospital, Tilburg) and MEG recording took place at a single centre (Amsterdam University Medical Centre, Vrije Universiteit Amsterdam) in The Netherlands. Consecutively referred patients from peripheral hospitals were included between August 2013 and March 2016. Patients were offered routine MEG in addition to EEG examination and MRI for the diagnosis of epilepsy. The final clinical diagnosis was based on all available clinical data and test results at the end of the diagnostic process. Sensitivity, specificity, and positive and negative predictive values were calculated for routine EEG, routine EEG plus additional EEG and MEG. In addition, diagnostic gain associated with MEG, relative to the other modalities, was calculated. Secondary outcome was congruence of localization of epileptiform discharges between MEG and MRI or final clinical diagnosis. Results. Based on a cohort of 138 patients, sensitivity and specificity was shown to be 31.6% and 78.4% for routine MEG, 31.6% and 100% for routine EEG, and 52.6% and 97.3% for routine EEG plus additional EEG, respectively. Routine MEG demonstrated a diagnostic gain of 16.8% compared to routine EEG and 9.5% compared to routine EEG plus additional EEG. In 35.7% of patients with a lesion on MRI that was consistent with the final clinical diagnosis, MEG showed epileptiform discharges in the same area. Conclusion. Routine MEG may provide additional value during the initial diagnosis of epilepsy

CCDC 135683: Experimental Crystal Structure Determination

Related Article: P.J.W.Deckers, A.J.van der Linden, A.Meetsma, B.Hessen|2000|Eur.J.Inorg.Chem.||929|doi:10.1002/(SICI)1099-0682(200005)2000:5<929::AID-EJIC929>3.0.CO;2-7,An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.

Characterisation, degradation and regeneration of luminescent Ag29 clusters in solution

Luminescent Ag clusters are prepared with lipoic acid (LA) as the ligand. Using a combination of mass spectrometry, optical spectroscopy and analytical ultracentrifugation, the clusters are found to be highly monodisperse with mass 5.6 kDa. We assign the chemical composition [Ag29(LA)12](3-) to the clusters, where LA likely binds in a bidentate fashion. The Ag29 clusters show slow degradation, retaining their deep red emission for at least 18 months if stored in the dark. Purification or exposure to light results in faster degradation. No other cluster species are observed during the degradation process. Once degraded, the clusters could easily be regenerated using NaBH4, which is not usually observed for thiolate-capped Ag clusters

Anti-angiogenesis and anti-tumor activity of recombinant anginex

Anginex, a synthetic 33-mer angiostatic peptide, specifically inhibits vascular endothelial cell proliferation and migration along with induction of apoptosis in endothelial cells. Here we report on the in vivo characterization of recombinant anginex and use of the artificial anginex gene for gene therapy approaches. Tumor growth of human MA148 ovarian carcinoma in athymic mice was inhibited by 80% when treated with recombinant anginex. Histological analysis of the tumors showed an approximate 2.5-fold reduction of microvessel density, suggesting that angiogenesis inhibition is the cause of the anti-tumor effect. Furthermore, there was a significant correlation between the gene expression patterns of 16 angiogenesis-related factors after treatment with both recombinant and synthetic anginex. To validate the applicability of the anginex gene for gene therapy, stable transfectants of murine B16F10 melanoma cells expressing recombinant anginex were made. Supernatants of these cells inhibited endothelial cell proliferation in vitro. Furthermore, after subcutaneous injection of these cells in C57BL/6 mice, an extensive delay in tumor growth was observed. These data show that the artificial anginex gene can be used to produce a recombinant protein with similar activity as its synthetic counterpart and that the gene can be applied in gene therapy approaches for cancer treatment

Characterisation, degradation and regeneration of luminescent Ag29 clusters in solution

Luminescent Ag clusters are prepared with lipoic acid (LA) as the ligand. Using a combination of mass spectrometry, optical spectroscopy and analytical ultracentrifugation, the clusters are found to be highly monodisperse with mass 5.6 kDa. We assign the chemical composition [Ag29(LA)12](3-) to the clusters, where LA likely binds in a bidentate fashion. The Ag29 clusters show slow degradation, retaining their deep red emission for at least 18 months if stored in the dark. Purification or exposure to light results in faster degradation. No other cluster species are observed during the degradation process. Once degraded, the clusters could easily be regenerated using NaBH4, which is not usually observed for thiolate-capped Ag clusters